For the growth of India's pharmaceutical sector, prioritizing innovation and advanced manufacturing is essential. Experts indicate that inc...

Biocon shares rose after its US subsidiary received supplemental FDA approval for Yesintek single-dose prefilled autoinjectors in two stren...

Thermo Fisher Scientific is amplifying its investment footprint in India, driven by the strong anticipated growth in the biosimilars and in...

During the first quarter of fiscal 2027, India's pharmaceutical exports soared to $8.10 billion, showcasing remarkable strength in drug for...

What is volatility? There is, of course, a mathematical definition. Then there is the human definition, which is how investors feel it. In ...

Zydus Lifesciences reported a significant year-on-year decline of thirty-six percent in net profit for the first quarter, despite a robust ...

2026 Independence Day: India's pharmaceutical industry marks a historic milestone with a new drug approval. This achievement reflects decad...

For Indian pharma, the regulatory risk is still real. A US FDA inspection can still cause trouble. A plant making an important product or g...

A word of caution for all those who have exposure to mid cap stocks or are planning to increase it. Just keep one thing in mind: If there i...

Indian companies are increasingly pursuing strategic overseas acquisitions. They now focus on acquiring capabilities and technology rather ...

The ET Health Conclave 2026 celebrated healthcare professionals and institutions. Leaders shared insights on healthcare infrastructure and ...

India's pharmaceutical industry is expected to reach$80-90 billion by 2030, well below its earlier$130 billion target, as U.S. tariff uncer...

IGI: Morgan Stanley stays bullish, citing strong certification-market growth and the company’s shift toward a consumer-focused business.Jin...

Biocon received Health Canada approval for its Yesintek autoinjector. This new format offers patients a convenient treatment option for pso...

The threat of a US tariff on Indian pharma is no longer a vague fear; or at least that is what President Trump wants us to believe. There i...

Indian pharmaceutical firms experienced a challenging June quarter, marked by declining US business profits. Dr Reddy's and Cipla saw signi...

The healthcare sector anticipates strong growth in domestic formulations and emerging markets. Companies with less US generics dependence w...